What we do

Specializing in clinical genomics and evolution in cancer.

Founded by and led by international leaders in cancer genomics and bioinformatics, Contextual Genomics delivers solutions that harness the clinical and genomic data of cancer patients to improve patient diagnosis and present expanded treatment options to oncologists and patients.

The tests Contextual Genomics engineer detect mutations in cancer, and have been designed to be medically necessary, clinical grade (CAP, CLIA validated), and cost effective. Our tests are embedded with leading, proprietary molecular quality assurance tools, enabling laboratory partners to effectively support their cancer physicians and patients.

Data driven medicine is part of a transformative paradigm resulting in ultra-high volume datasets that are revolutionizing medical practices and approaches. The proliferation of large databases of clinical, imaging, and molecular data are driving new biomedical discoveries and informing and enabling precision medical care.

Contextual Genomics’ approach to cancer care is inherently data intensive. We develop and deploy Next-Generation Sequencing tests to detect mutations in cancer DNA, then combine these results with clinical data. This results in high volume datasets which are analyzed and interpreted in relation to a patient’s clinical care. Our tests track the evolution of cancer under treatment and provide the data necessary to predict if patients are relapsing while on a given therapy. This allows for oncologists and patients to change treatment course early in disease management leading to improved outcomes.

Leadership Team

Contextual Genomics’ expertise in the provision and interpretation of genomic-based assays in cancer is unmatched. Our key strength lies in development and delivery of genomics based cancer diagnostics and bioinformatics. This stems from the extensive experience of our scientific and medical leaders, Drs. Samuel Aparicio, David Huntsman and Sohrab Shah.

Each has gained international recognition for their unparalleled work in the field of cancer research. Collectively, they have published >400 peer reviewed articles in the field of cancer genomics, diagnosis, and bioinformatics including in the New England Journal of Medicine, Science, Nature and Nature Genetics.

Board of Directors